Targeted Radioimmunotherapy and Theranostics with Alpha Emitters

Pandit-Taskar, 2003, New strategies in radioimmunotherapy for lymphoma, Curr Oncol Rep, 5, 364, 10.1007/s11912-003-0020-z Macklis, 1992, Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis, Radiat Res, 130, 220, 10.2307/3578279 Palayoor, 1993, G2M arrest and apoptosis in murine T lymphoma cells following exposure to 212Bi alpha particle irradiation, Nucl Med Biol, 20, 795, 10.1016/0969-8051(93)90166-R McDevitt, 1998, Radioimmunotherapy with alpha-emitting nuclides, Eur J Nucl Med, 25, 1341, 10.1007/s002590050306 Parker, 2018, Targeted alpha therapy, an emerging class of cancer agents: a review, JAMA Oncol, 4, 1765, 10.1001/jamaoncol.2018.4044 Pandit-Taskar, 2008, Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy, J Nucl Med, 49, 1066, 10.2967/jnumed.107.049502 Staudacher, 2014, Targeted alpha-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation, Nucl Med Commun, 35, 1284, 10.1097/MNM.0000000000000199 Sgouros, 2008, Alpha-particles for targeted therapy, Adv Drug Deliv Rev, 60, 1402, 10.1016/j.addr.2008.04.007 Huang, 2012, Microdosimetry for targeted alpha therapy of cancer, Comput Math Methods Med, 2012, 153212, 10.1155/2012/153212 Goldenberg, 2012, Pretargeted molecular imaging and radioimmunotherapy, Theranostics, 2, 523, 10.7150/thno.3582 Cheal, 2017, Curative multicycle radioimmunotherapy monitored by quantitative SPECT/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer, J Nucl Med, 58, 1735, 10.2967/jnumed.117.193250 Zeglis, 2013, A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry, J Nucl Med, 54, 1389, 10.2967/jnumed.112.115840 Zalutsky, 2008, Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6, J Nucl Med, 49, 30, 10.2967/jnumed.107.046938 Elgqvist, 2006, Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose, J Nucl Med, 47, 1342 Kramer, 2018, A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma, Pediatr Blood Cancer, 65, 10.1002/pbc.26754 Kramer, 2010, Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma, J Neurooncol, 97, 409, 10.1007/s11060-009-0038-7 Bailey, 2019, Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes, J Neurooncol, 143, 101, 10.1007/s11060-019-03139-6 Souweidane, 2018, Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial, Lancet Oncol, 19, 1040, 10.1016/S1470-2045(18)30322-X Rosenblat, 2010, Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia, Clin Cancer Res, 16, 5303, 10.1158/1078-0432.CCR-10-0382 Jurcic, 2014, Targeted alpha-particle immunotherapy for acute myeloid leukemia, Am Soc Clin Oncol Educ Book, e126, 10.14694/EdBook_AM.2014.34.e126 Pandit-Taskar, 2015, A Phase I/II study for analytic validation of 89Zr-J591 ImmunoPET as a molecular imaging agent for metastatic prostate cancer, Clin Cancer Res, 21, 5277, 10.1158/1078-0432.CCR-15-0552